MicroRNAs (miRNAs) are small, non-coding RNAs that can act as oncogenes or tumor suppressor genes in human cancer. Emerging evidence indicates that deregulation of miRNAs contributes to the hepatocarcinogenesis. In the present study, we demonstrated that the levels of miR-520e were dramatically decreased in examined hepatoma cell lines and clinical hepatocellular carcinoma (HCC) tissues. Moreover, we found that DNA hypermethylation in the upstream region of miR-520e resulted in the downregulation of miR-520e. Next, we demonstrated that introduction of miR-520e dramatically suppressed the growth of hepatoma cells in vitro and in vivo, whereas silencing the expression of miR-520e by anti-miR-520e resulted in a promoted cell proliferation, suggesting that miR-520e may be a novel tumor suppressor. Further studies revealed that NF-jB-inducing kinase (NIK) was one of the direct target genes of miR-520e, as miR-520e directly bound to the 3 0 untranslated region of NIK, which reduced the expression of NIK at the levels of mRNA and protein. Moreover, silencing of NIK was able to inhibit the growth of hepatoma cells, similar to the effect of miR-520e overexpression on growth of hepatoma cells. Meanwhile, the knockdown of NIK expression reversed the enhanced proliferation mediated by anti-miR-520e. In addition, miR-520e significantly decreased the phosphorylation of ERK1/2 (p-ERK1/2) and depressed the transcriptional activity and nuclear translocation of nuclear factor jB (NF-jB) (p65). These results suggest that miR-520e suppresses the growth of hepatoma cells by targeting NIK involving the NIK/p-ERK1/2/NF-jB signaling pathway. Finally, we showed that the intratumoral injection with miR-520e was able to directly repress the growth of hepatoma cells in the nude mice. Thus, our finding provides new insight into the mechanism of hepatocarcinogenesis, indicating a therapeutic potential of miR-520e in the treatment of HCC.
Introduction
MicroRNAs (miRNAs) are small, non-coding RNA of approximately 19-25 nucleotides that negatively modulate gene expression through RNA-induced silencing complexmediated mRNA cleavage or translational repression when partially complementary sequences are present in the 3 0 untranslated regions (3 0 UTRs) of the target mRNAs (Bartel, 2004; Bartel and Chen, 2004) . miRNAs are phylogenetically conserved and have critical roles in variety of biological processes, including development, differentiation, apoptosis, cell proliferation, metabolism and immunity Kim, 2005) . The development of microarray for the analysis of miRNA expression revealed that multiple miRNAs are aberrantly expressed in human malignancies (Croce and Calin, 2005; Gregory and Shiekhattar, 2005) . Emerging evidence in the molecular characterization of miRNAs suggests that they may represent a novel class of oncogenes or tumorsuppressor genes Croce, 2006, 2007; Kent and Mendell, 2006) . Hepatocellular carcinoma (HCC) is the fifth most common malignant cancer and the third leading cause of cancer death worldwide with annual death exceeding 600 000 (El-Serag and Rudolph, 2007) . As in other solid tumors, the development and progression of HCC are associated with additional genetic and epigenetic alterations (Farazi and DePinho, 2006) . However, the evidence accumulated so far can not explain the full mechanism of hepatocarcinogenesis. Recent studies have emphasized the causative links between miRNA deregulations and cancer development. miRNAs have been discovered to be aberrantly expressed in HCC and some of them are functionally involved in hepatocarcinogenesis and progression (Gramantieri et al., 2008; Jiang et al., 2008; Ji and Wang, 2009) . It has been reported that the epigenetic modifications, especially DNA hypermethylation, might have crucial roles in the initiation of HCC. Growing evidence supports a role for miRNAs as both targets and effectors in aberrant mechanisms of DNA hypermethylation. Some miRNAs have been reported to be inactivated in human tumors by the aberrant hyper-methylation of CpG islands (Saito et al., 2006; Datta et al., 2008) . Recently, it has been reported that miR-520e is downregulated in hepatoma HepG2 cell line by microarray analysis of miRNA (Li et al., 2010) . Our groups have reported that miR-520e is downregulated in breast cancer cells and sensitizes breast cancer cells to complement attack by directly targeting the 3 0 UTR of CD46 (Cui et al., 2010) . However, the functional attributes of miR-520e associated with HCC progression have not been experimentally established.
With DNA microarray assay, several signaling pathways are potentially involved in HCC development and progression through the modulation of multiple mRNAs (Gramantieri et al., 2007) . The NF-kB-inducing kinase (NIK) is a member of mitogen-activated protein kinase kinase kinase (MAP3K) family that potently participates in the activation of nuclear factor kB (NF-kB), a family of eukaryotic transcription factors that mediate cell growth and transformation. NIK is identified by means of its association with TNF receptor-associated factor 2. Some studies demonstrate that NIK induces the mitogen-activated protein kinase kinase 1 (MEK1) phosphorylation and activates the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway in tumor cells (Foehr et al., 2000; Dhawan and Richmond, 2002) .
In the present study, we aim to elucidate the pathophysiological role of miR-520e in hepatocarcinogenesis. Our finding shows that miR-520e is downregulated in hepatoma cell lines and clinical HCC tissues, suggesting that miR-520e might act as a tumor suppressor. We identified that NIK is one of the direct target genes of miR-520e. miRNA-520e is able to suppress the growth of hepatoma cells through targeting NIK involving NIK/p-ERK1/2/NF-kB signaling pathway.
Results
Expression of miR-520e is frequently reduced in hepatoma cell lines and HCC tissues The previous miRNA profiling showed that miR-520e was downregulated in hepatoma cells and cholangiocarcinomas (Selaru et al., 2009; Li et al., 2010) . To further confirm and extend this finding, we analyzed the expression of miR-520e in 2 immortalized liver cell lines, 3 human hepatoma cell lines, 23 paired clinical HCCs and adjacent nontumorous liver tissues using quantitative real-time PCR (qRT-PCR) and normalized against an endogenous control (U6 RNA). The data showed that miR-520e was downregulated in all the three hepatoma cell lines (Figure 1a ). When compared with their nontumorous counterparts, significant downregulation of miR-520e was observed in all the 23 HCC samples. We found that the median miR-520e expression level in primary HCCs was fivefold lower than that of the nontumorous livers (Figure 1b) . These results suggest that the reduced miR-520e expression is a frequent event in human hepatoma cells and HCC tissues, which may be involved in hepatocarcinogenesis.
DNA methylation is responsible for the downregulation of miR-520e Like protein-coding mRNAs, miRNAs are also transcribed from their genes in genomic DNA. It has been reported that the epigenetic mechanisms, such as DNA methylation and histone modifications, can affect the expressions of miRNAs (Saito et al., 2006) . Recently, several miRNAs were found to be epigenetically silenced in association with CpG island hypermethylation in cancer cells (Lujambio et al., 2007) . To investigate the mechanism of downregulation of miR-520e, we analyzed the upstream region of its coding sequence in the human genome using some software, such as CpG Island Searcher (http://cpgislands.usc.edu/) and Methyl Primer Express Software v1.0. We noted that there was a typical CpG island from À850 to À546 within the upstream region of miR-520e. Then, we examined DNA methylation at the upstream region of miR-520e coding sequence by methylation-specific PCR and bisulfitesequencing analysis. Results showed that the CpG sites Figure 1 Expression of miR-520e is frequently reduced in hepatoma cells and HCC tissues. (a) qRT-PCR analysis of miR520e expression in hepatocytes and hepatoma cells and normalized against an endogenous control (U6 RNA). Data were analyzed using a DDCt approach and expressed as either miR-520e/U6 ratio (À2 DCt(miRÀ520eÀU6) ). The expression of miR-520e was normalized to U6 with respect to Chang liver cells. One-way analysis of variance was used to compare miR-520e expression in all individual hepatocytes with all hepatoma cell lines. Data are reported as mean±s.d. for three independent experiments (***Po0.001, Student's t-test). (b) qRT-PCR analysis of miR-520e expression in 23 paired HCC tissues and their corresponding nontumorous livers. The expression of miR-520e was normalized to U6 with respect to specimen N1. miR-520e expression in HCC tissues and nontumorous liver tissues were compared by way of Wilcoxon signed-rank test (***Po0.001, Student's t-test).
miR-520e inhibits growth of hepatoma cells S Zhang et al were highly methylated in hepatoma cells and HCC tissues. In contrast, the CpG sites were unmethylated in normal liver cell lines and nontumorous liver tissues (Figures 2a and b) . To identify whether the downregulation of miR-520e is induced by DNA hypermethylation in hepatoma cell lines and HCC tissues, it is conceivable that demethylating treatment might upregulate miR-520e levels. To address this issue, we treated HepG2 cells with the 5 mM 5-Aza-2 0 -deoxycytidine (DNA methylation inhibitors, Aza) for 72 h. Next, we carried out qRT-PCR analysis for pri-miR-520e and miR-520e expression in HepG2 cells, respectively. As shown in Figure 2c , the expression levels of pri-miR520e and miR-520e were dramatically increased by the miR-520e inhibits growth of hepatoma cells S Zhang et al miR-520e inhibits growth of hepatoma cells S Zhang et al Aza treatment. As epigenetic treatment remarkably upregulated the expression of miR-520e, our data showed that the treatment decreased the methylation status of endogenous miR-520e CpGs (nucleotides À850 to À546) (Figures 2d and e) . As miR-520e was methylated and silenced in hepatoma cell lines and HCC tissues, we made several reporter constructs containing different portions of the miR-520e upstream sequence to define the required region. As shown in Figure 2f , the pGL3-miR-520e-no. 2, -no. 3 and -no. 4 constructs displayed high promoter activities, whereas the pGL3-miR-520e-no. 1 and -no. 5 constructs failed to show strong promoter activities, suggesting that the region from À850 to À546 bp containing the CpG island hypermethylation is the core promoter of miR-520e. The data further support that the silencing of the expression of miR-520e in HCC may be attributed to the methylation status of CpG islands because the CpG islands are localized in the region of promoter. Thus, the aberrant promoter DNA methylation and miR-520e silencing might contribute to the growth of hepatoma cells. The miR-520e gene is located in 19q13.42 and is reported to be in the largest miRNA gene cluster in human (Li et al., 2009a) . To demonstrate the role of methylation in the regulation of miRNAs, we carried out qRT-PCR analysis for miR-498, miR-519e and miR-515-1 in HepG2 cells after treatment with 5 mM Aza for 72 h. As shown in Supplementary Figure S1 , the expression levels of miR-498, miR-519e and miR-515-1 were dramatically increased by the Aza treatment, suggesting that the expression of miR-498, miR-519e and miR-515 may be regulated by DNA methylation for CpG islands. Thus, we conclude that the silencing of miR-520e expression is attributed to the methylation status of CpG islands in hepatoma cells.
miR-520e suppresses growth of hepatoma cells in vitro and in vivo To examine the potential role of miR-520e in tumorigenesis, we sought to determine whether miR520e affects the growth of hepatoma cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and 5-ethynyl-2 0 -deoxyuridine incorporation assay, respectively. Hepatoma HepG2 and H7402 cells, which have a very low basal level of miR-520e, were transfected with miR-520e mimic (miR-520e) or negative control (NC). Then, the expression levels of miR520e were examined by qRT-PCR (Supplementary Figure S2 ). As indicated in Figures 3a and b, the growth of hepatoma cells transfected with miR-520e was significantly decreased relative to NC-transfected cells.
Because the expression level of miR-520e was very low in hepatoma cell lines, we selected the immortalized human liver cell lines, such as Chang liver and L-O2, which have a relatively high level of miR-520e, to estimate the effects of miR-520e on the inhibition of cell growth. Interestingly, the transfection of anti-miR-520e (miR-520e inhibitor) in the two cell lines resulted in the increase of cell proliferation relative to the negative control (anti-miR-NC) (Figures 3a and b) . Similar results were obtained when hepatoma HepG2 cells were transfected with anti-miR-520e or Chang liver cells were transfected with miR-520e (Supplementary Figure S3) . The expression levels of miR-520e were confirmed by qRT-PCR (Supplementary Figure S2) . In addition, the reduction of cell proliferation was observed in hepatoma cells after treatment with Aza (Supplementary Figure S4) . The data suggest that miR-520e has a crucial role in suppressing the growth of hepatoma cells. Moreover, colony formation assay showed that the enforced expression of miR-520e resulted in a more than 50% decrease in colony numbers in hepatoma HepG2 (or MHCC-97L) cells transfected with miR-520e compared with NC ( Figure 3c ). To further determine the effect of miR-520e on hepatoma cell growth in vivo, the HepG2 cells transiently transfected with miR-520e or NC were subcutaneously injected into 4-6-week-old BALB/c athymic nude mice. The mice were followed for observation of xenograft growth for 4 weeks. After 30 days, the mice were killed and the tumors were weighed. We found that the introduction of miR-520e into HepG2 cells led to a significant reduction in both the size of tumor volume and the frequency of tumor formation (NC versus miR-520e transfectants, 5/5 versus 4/5) (Figures 4a and b) . The tumor weight of the miR-520e-transfected HepG2 cells was significantly lower than that of NC-transfected HepG2 cells (Figure 4c ). Meanwhile, the expression levels of miR-520e in the tumor tissues from the animal were showed by qRT-PCR analysis ( Figure 4d ). Taken together, both in vitro and in vivo studies suggest that miR-520e significantly inhibits the growth of hepatoma cells.
miR-520e directly inhibits the expression of NIK through its 3
0 UTR To explore the mechanisms underlying miR-520e-suppressed tumor growth, predicted target genes of miR-520e in human were retrieved from the TargetScan (http://www.targetscan.org/) and DIANA database (http://diana.cslab.ece.ntua.gr/microT/). Several genes, which have been reported to promote cell proliferation, were selected for further analysis. Among them, NIK Figure 3 miR-520e suppresses growth of hepatoma cells in vitro. (a) HepG2 and H7402 cells were transfected with 100 nM NC and 100 nM miR-520e, respectively. Chang liver and L-O2 cell lines were transfected with 200 nM anti-miR-NC and 200 nM anti-miR-520e, respectively. The effects of miRNAs on cell proliferation were determined by by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay at 24, 48 and 72 h after transfection. (b) HepG2 cells were transfected with 100 nM NC and 100 nM miR-520e, respectively. Chang liver cells were transfected with 200 nM anti-miR-NC and 200 nM anti-miR-520e, respectively. The cell proliferation was examined by 5-ethynyl-2 0 -deoxyuridine incorporation assay at 48 h after transfection. (c) HepG2 and MHCC-97L cells were transfected with 100 nM NC and 100 nM miR-520e, respectively. The growth of cells was detected by colony formation at very low cell density. Data are reported as mean ± s.d. for three independent experiments (*Po0.05; **Po0.01; ***Po0.001, Student's t-test).
miR-520e inhibits growth of hepatoma cells S Zhang et al (MAP3K14, NM_003954.2) was of particular interest, because it was found to be upstream of NF-kB and correlated with growth of cancer cells, including human prostate cancer, breast cancer and melanotic cancer (Foehr et al., 2000; Dhawan and Richmond, 2002; Nishina et al., 2009; Yamaguchi et al., 2009) . As shown in Figure 5a , there was a miR-520e binding site at nt1033-1039 of the NIK 3 0 UTR. Comparing the human sequence with interspecies homology, we found that the miR-520e target sequence at nt1033-1039 of the NIK3 0 UTR was highly conserved among different species (Figure 5a , upper portion). To determine whether NIK is a direct target of miR-520e, we constructed pGL3-NIK-3 0 UTR-wt and pGL3-NIK-3 0 UTRmu (Figure 5a , lower portion). Cotransfection of miR520e significantly suppressed the firefly luciferase activity of pGL3-NIK-3 0 UTR-wt but not that of pGL3-NIK-3 0 UTR-mu in HepG2 cells (Figure 5b ). In addition, inhibition of endogenous miR-520e by anti-miR-520e led to increased firefly luciferase activity of the wild-type reporter but not that of the mutant one in Chang liver cells (Figure 5c ). Similar results were obtained when hepatoma HepG2 cells were transfected with anti-miR520e or Chang liver cells were transfected with miR-520e (Supplementary Figure S6) . Luciferase activities of hepatoma cells transfected with pGL3-NIK-3 0 UTR-wt were significantly lower after epigenetic treatment, whereas those transfected with pGL3-NIK-3 0 UTR-mu showed no significant difference (Figure 5d ). To test whether miR-520e expression affects endogenous NIK expression, we transfected miR-520e or NC into HepG2 cells, a decrease of NIK mRNA and protein level was observed (Figure 5e ). Meanwhile, the expression levels of NIK were decreased in the tumor tissues by animal treatment with miR-520e (Supplementary Figure S5) . Consistent with these results, silencing of miR-520e in Chang liver cells showed an increase of NIK mRNA and protein level (Figure 6e , lower portion). The expression level of NIK was significantly downregulated in hepatoma cells after treatment with Aza (Figure 5f ). Taken together, these data imply that miR-520e may attenuate the expression of NIK by directly targeting its 3 0 UTR.
NIK contributes to miR-520e-suppressed cell growth
We then examined mRNA and protein levels of NIK in two hepatocytes, three hepatoma cells and 23 paired clinical HCC and adjacent nontumorous liver tissues. Our data revealed that the expression of NIK was upregulated in hepatoma cells relative to hepatocytes, as well as in HCC tissues compared with adjacent nontumorous liver tissues (Figures 6a and b) . Correlation between the miR-520e level and the expression of NIK was further examined in HCC tissues. Markedly, miR520e level was inversely correlated with NIK expression ( Figure 6c ). Next, we investigated whether NIK increased the growth of HepG2 cells. NIK has been reported to increase the cell proliferation of pancreatic miR-520e inhibits growth of hepatoma cells S Zhang et al cancer cells (Nishina et al., 2009) . As shown in Figure 6d , upper portion, silencing of NIK by small interfering RNA (siRNA) in HepG2 cells led to decreased cell proliferation, demonstrating a positive role of NIK protein in the growth of hepatoma cells. To further establish a functional connection between miR520e and NIK, we tested whether NIK was required for effect of miR-520e on cell proliferation. Overexpression of anti-miR-520e was able to promote cell proliferation in Chang liver cells. The effect of anti-miR-520e on cell proliferation was partially attenuated by siRNA targeting human NIK mRNA (si NIK) when si NIK and antimiR-520e were co-transfected into Chang liver cells (Figure 6e , upper portion). In parallel, the mRNA and protein levels of NIK were confirmed by reverse transcription-PCR (RT-PCR) and western blot analysis (Figure 6d , lower figures). In addition, western blot analysis confirmed that the expression levels of NIK in the tumor tissues from the animal in Figure 4b were downregulated by pre-treatment with miR-520e in HepG2 cells (Supplementary Figure S6) . These results indicate that NIK serves as a target of miR520e, contributing to the effect of miR-520e on cell proliferation. miR-520e inhibits growth of hepatoma cells S Zhang et al miR-520e inactivates ERK1/2 and NF-kB signaling through NIK The MAPK family includes three distinct subfamilies: the extracellular signal-regulated protein kinases (ERKs), including ERK1 and ERK2, the stress-activated cJNKs and p38 kinase (Roux and Blenis, 2004) . ERK1/2 is one of the downstream effectors of NIK (Foehr et al., 2000; Dhawan and Richmond, 2002) . Accordingly, to further investigate the possible molecular mechanisms of miR-520e-induced cell proliferation repression, we detected the phosphorylation of ERK1/2 after transfection with miR-520e in HepG2 cells or with anti-miR-520e in Chang liver cells. The results demonstrated that phosphorylation of ERK1/2 (p-ERK1/2) was markedly The expression of NIK was normalized to GAPDH with respect to specimen N1. Statistical differences were analyzed with the Wilcoxon signed-rank test (***Po0.001, Student's t-test). (c) Inverse correlation between miR-520e and NIK expression in HCC tissues. Expression of NIK analyzed by qRT-PCR and normalized to GAPDH. The miR-520e expression was examined by qRT-PCR analysis and normalized to U6 expression. Statistical analysis was performed using Pearson's correlation coefficient (r ¼ À0.677, Po0.001). (d, e) MTT assay was performed to determine the growth of HepG2 (or Chang liver) cells treated with si NIK (or both si NIK and anti-miR-520e) (upper portion). Data are reported as mean±s.d. for three independent experiments (**Po0.01; ***Po0.001, Student's t-test). RT-PCR and western blot analysis were performed to determine the expression level of NIK (lower portion). The intensity for each band was densitometrically quantified.
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decreased by miR-520e overexpression, whereas p-ERK1/2 was noticeably increased by silencing of miR-520e (Figures 7a and b) . However, the phosphorylation of JNK and p38 was not affected by miR-520e (Supplementary Figure S7a ). In parallel, we examined the level of p-ERK1/2 in hepatocyte and hepatoma cells (Supplementary Figure S7b) . It is well established that NF-kB is regulated through the NIK-MEKMAPK-NFkB signaling pathway (Dhawan and Richmond, 2002) . We then examined the effect of miR-520e on NF-kB transcriptional activity and found that miR-520e decreased the promoter activity of NF-kB in HepG2 cells and anti-miR-520e increased the promoter activity of NF-kB in Chang liver cells by luciferase reporter gene assay (Figures 7c and d) . The nuclear translocation of NF-kB/p65 is preceded by the phosphorylation, ubiquitination and proteolytic degradation of IkBa (Hayden and Ghosh, 2008) . According to this, NF-kB is a downstream effector of MAPK (Chen et al., 2007; Mercatelli et al., 2008) , we examined the effect of p-ERK1/2 on the translocation of the NF-kB and IkB degradation. The data showed that the translocation of NF-kB/p65 to the nucleus was inhibited and p-IkBa was decreased in the cytoplasm when the hepatoma cells were treated with MEK1 inhibitor PD98059 (Supplementary Figure S8 ). Then, we investigated whether miR-520e reduces the nuclear translocation of NF-kB/ p65 and IkB degradation in the cells. Analysis of the cytoplasmic-nuclear shuttling revealed a substantial decrease in NF-kB/p65 in the nuclear fractions and pIkBa in the cytoplasmic fractions of miR-520e-treated HepG2 cells compared with those in control (Figure 7e ). In contrast, there was an increase in the anti-miR-520e-treated Chang liver cells (Figure 7f ). To further confirm the mechanism, we co-transfected Chang liver cells with si NIK and anti-miR-520e, and found that si NIK was The NF-kB promoter activity was examined by luciferase reporter gene assay. Data are reported as mean ± s.d. for three independent experiments (*Po0.05; **Po0.01, Student's t-test). (e, f) The nuclear extracts were analyzed for NF-kB/p65 and cytoplasmic extracts were assayed for p-IkBa by western blot analysis. Histone3 or b-actin was used as an internal control. The intensity for each band was densitometrically quantified.
miR-520e inhibits growth of hepatoma cells S Zhang et al able to partially abolish the effects of anti-miR-520e on p-ERK1/2, activity of NF-kB and nuclear translocation of NF-kB/p65, and IkB degradation in the cells (Figures 7b, d and f) . In addition, the NF-kB transcriptional activity was decreased in hepatoma cells by the treatment with Aza (Supplementary Figure S9) . Thus, our data suggest that miR-520e suppresses hepatoma cell growth through NIK/p-ERK1/2/NF-kB signaling pathway.
The intratumoral injection with miR-520e inhibits the growth of HepG2 cells in mice Accordingly, we supposed that miR-520e might be a novel candidate for hepatoma therapy. Then, we tested whether miR-520e could suppress tumor growth in a xenograft model. Surprisingly, as shown in Figures 8a and b, the tumors intratumorally injected with synthetic miR-520e were significantly smaller than those with NC at 9, 12 and 15 days after the first injection. The average tumor weights for the NC-and the synthetic miR-520e-inoculated mice were 0.654 and 0.099 g, respectively, at day 30 (Figure 8c) . Meanwhile, the expression levels of miR-520e and NIK in the tumor tissues from the animal were examined by qRT-PCR analysis and western blot analysis, respectively. The data confirmed that miR-520e targeting NIK was responsible for the inhibition of tumor growth in mice (Figures 8d and e) . Thus, our experimental data may provide a strategy for targeting with the miR520e/NIK as a novel therapeutic application to treat HCC patients.
Discussion
HCC is a heterogeneous tumor that develops by the activation of multiple pathways and molecular alterations. In general, deregulated cell proliferation has a major role in HCC. miRNAs are involved in HCC pathogenesis and their expression profiles have been used to classify cancers (Lu et al., 2005) . Therefore, it is reasonable to expect that deregulation of cell proliferation-related miRNAs may facilitate tumorigenesis. Xu et al. (2009) indicated that miR-195 may suppress tumorigenicity and regulate G1/S transition of HCC cells by repressing Rb-E2F signaling through targeting multiple molecules, including cyclin D1, CDK6 and E2F3. Liang et al. (2010) reported that miR-125b was able to suppress tumor growth in hepatic carcinogenesis through the suppression of oncogene LIN28B expression. In addition, our groups also observed the deregulation of miR-520e in breast cancer cells (Cui et al., 2010) . We are interested in the role of miR-520e in tumorigenesis. However, little is known about the role and underlying molecular mechanism of miR-520e in the development of HCC. In this study, we found that miR-520e was frequently downregulated in hepatoma cell lines and clinical HCC tissues (Figure 1) . Thus, we supposed that miR-520e may be a novel tumor-suppressor miRNA. However, the underlying mechanism responsible for the decreased expression of miR-520e in HCC remains unclear. Knowing that epigenetics can control the expression of many protein-coding genes, and that miRNAs are also generally transcribed by RNA polymerase II, it is reasonable to hypothesize that epigenetics can have fundamental roles in controlling miRNA expression. Many miRNAs are located in the introns of proteincoding genes (Kim and Nam, 2006) . It is believed that such miRNAs are co-regulated with their host genes (Ying and Lin, 2005) . However, it is possible that these miRNAs can have their own promoters. It has been reported that CpG islands within introns can act as promoters that are regulated by DNA methylation (Lyle et al., 2000) . Along a 340-bp sequence (nucleotides À203 to 137) containing miR-223, DNA methylation of six CpG dinucleotides has been reported to contribute to miRNA repression (Fazi et al., 2007) . Notably, miR520e is located at chromosome 19q13.42, locus spans a large, poorly characterized miRNA cluster (Li et al., 2009a) . The amplification of chromosome region 19q13.42 is common in both ependymoblastoma and embryonal tumor (Gessi et al., 2011) . In addition, we are able to computationally map a CpG-enriched region upstream of the miR-520e gene. Then, we examined DNA methylation at the upstream region of miR-520e by methylation-specific PCR and bisulfite genomic sequencing (Figures 2b and c) . In this case, we first identified the miR-520e promoter region. Consistency in the correlation between promoter methylation status (CG sites from nucleotides À850 to À546) and expression patterns suggests that aberrant promoter methylation contributes to the lower expression of miR-520e in hepatoma HepG2 cell line. Interestingly, we showed that the treatment with Aza upregulated the expression of miR-520e and decreased the methylation status of endogenous miR-520e CpG in hepatoma cells. Thus, our finding suggests that the methylation of endogenous miR-520e CpGs is associated with reversible miR-520e silencing. Therefore, we conclude that DNA hypermethylation is responsible for the downregulation of miR-520e in hepatoma cells.
Next, we investigated the function of miR-520e in hepatocarcinogenesis. Our data showed that the reintroduction of miR-520e dramatically repressed the cell proliferation of hepatoma cells in vitro and tumor growth in vivo (Figures 3 and 4) . Therefore, our data suggest that the reduced expression of miR-520e may contribute to the promotion of cell proliferation and consequently facilitate the development of cancers like HCC. We further characterized NIK as a functional target of miR-520e by luciferase reporter gene assays, RT-PCR and western blot analysis, respectively (Figures 5b, c and e) . NIK is a member of the mitogenactivated protein kinase kinase kinase family that may either directly or indirectly phosphorylate or activate IKKa/b, leading to the phosphorylation and degradation of IkBa followed by NF-kB activation. Foehr et al., 2000 have recently demonstrated that NIK regulates differentiation of PC-12 cells through MEK/ERK pathways. Rangaswami et al. (2004) reported that NIK has a crucial role in OPN-induced NF-kB activation, uPA secretion and pro-MMP-9 activation through MAPK/IKKa/b-mediated pathways, and all of these ultimately control tumor growth. The NF-kB family is composed of five related transcription factors: p50, p52, RelA (p65), c-Rel and RelB. In classical NFkB activation, signals mediated by MAP/ERK kinase kinase 3 (MEKK3) and IKKb finally result in the degradation of IkBa and the translocation of the RelA/ p50 homodimer to the nucleus. In the alternative NF-kB activation pathway, signals triggered by CD40, LTbR or BAFF-R are mediated by NIK and IKKa, which leads to p100 processing and the translocation of p52 dimers to the nucleus (Brown et al., 2008) . NIK has a vital role in activating NF-kB in the alternative NF-kB activation pathway usually. However, in this study we observed that NIK was able to activate NF-kB/p65 (Figure 7 and Supplementary Figure S8) . Interestingly, p-ERK1/2 is responsible for the activation. Thus, we conclude that NIK is involved in the classical NF-kB pathways of p50-p65 activation. Moreover, we observed that the growth of tumor was efficiently inhibited by direct injection with miR-520e in mice (Figure 8 ). The expression levels of NIK were downregulated in the tumor tissues. Therefore, we conclude that miR-520e has a pivotal role in repressing tumor growth through targeting NIK.
In summary, we investigated the role of miR-520e in hepatocarcinogenesis. Our finding suggests that miR520e may be a novel tumor-suppressor miRNA. miR520e blocks the growth of hepatoma cells through targeting NIK involving NIK/p-ERK1/2/NF-kB signaling pathway. Our data provide new insight into the mechanism of hepatocarcinogenesis. Additionally, miR520e may serve as a potential therapeutic candidate in the treatment of HCC.
Materials and methods

Cell lines
The immortalized human liver L-O2, Chang liver cells and human hepatoma H7402 cells were maintained in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with heatinactivated 10% fetal bovine serum (Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin at 37 1C with 5% CO 2 . The human hepatoma cell lines, HepG2 and MHCC-97L, were maintained in Dulbecco's modified Eagle's medium (Gibco) supplemented with heat-inactivated 10% fetal bovine serum (Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin at 37 1C with 5% CO 2 .
Tissue specimens Paired HBV-related HCC and adjacent nontumorous liver tissues were collected from patients undergoing resection of HCC in Tianjin First Center Hospital (Tianjin, PR China). The relevant characteristics of the studied subjects were shown miR-520e inhibits growth of hepatoma cells S Zhang et al in Supplementary Table S1 . Informed consent was obtained from each patient and the study was approved by the Institute Research Ethics Committee at Nankai University.
Oligonucleotides and plasmids
The miR-520e mimic (miR-520e), mimic NC, miR-520e inhibitor (anti-miR-520e), inhibitor NC (anti-miR-NC), the siRNAs targeting human NIK (GenBank accession no. NM_003954.2) mRNA (si NIK) and NC siRNA (si Control) were purchased from RiboBio (Guangzhou, China). All oligonucleotide sequences are listed in Supplementary Table S2 .
An B700-bp fragment of NIK 3 0 UTR was subcloned into the pGL3 control vector (Promega, Madison, WI, USA) immediately downstream of the stop codon of the luciferase gene to generate pGL3-NIK-3 0 UTR-wt. Mutant construct of NIK 3 0 UTR, named as pGL3-NIK-3 0 UTR-mu, which carried a substitution of six nucleotides within the core seed sequence of miR-520e, was carried out using overlapping extension PCR. A genomic miR-520e upstream gene region was amplified using the primers and cloned into pGL3-Basic plasmids, between the KpnI and HindIII sites (Promega). All primers are listed in Supplementary Table S2 .
Cell transfection RNA oligonucleotides were transfected using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA). A final concentration of 100 nM miR-520e, 200 nM anti-miR-520e or 100 nM si NIK was used unless indicated. RNA transfection efficiency was approximately 70-80% and the overexpression of miRNA or siRNA persisted for at least 2 days. Lipofectamine 2000 (Invitrogen) was used for transfection of plasmid alone or together with RNA oligonucleotides.
qRT-PCR, RT-PCR and western blot analysis Total RNA was extracted from the cells (or tumor tissues) using Trizol (Invitrogen) according to the manufacturer's protocol. For pri-miR-520e or mature miR-520e, miR-498, miR-519e and miR-515 detection, total RNA was polyadenylated by poly (A) polymerase (Ambion, Austin, TX, USA) as described previously (Li et al., 2009b) . Reverse transcription was performed using poly (A)-tailed total RNA and reverse transcription primer with ImPro-II Reverse Transcriptase (Promega) according to the manufacturer's protocol. For NIK mRNA level detection, the total RNA from those cells (or tissues) was directly reverse transcribed. The qRT-PCR was performed as described in the method of SYBR Premix Ex TaqTM II Kit (Takara, Ohtsu, Japan). All primers are listed in Supplementary Table S2 .
Western blot analysis was performed as previously described . The primary antibodies used for western blot were rabbit polyclonal anti-NIK (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse monoclonal anti-b-actin (Cell Signaling Technology, Beverly, MA, USA), rabbit monoclonal anti-p-ERK1/2 and anti-total-ERK1/2 (Cell Signaling Technology), mouse monoclonal anti-NF-kB p65 (Santa Cruz Biotechnology) and rabbit polyclonal anti-Histone3 (Cell Signaling Technology).
5-Aza-2
0 -deoxycytidine (Aza) treatment and methylation analysis The cells were treated with 5 mM Aza (the DNA methylation inhibitor) (Sigma, St Louis, MO, USA) for 72 h. Cells were harvested and RNA was extracted for qRT-PCR analysis. Genomic DNA (2 mg) was modified with sodium bisulfite using an EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA). Methylation-specific PCR and bisulfite-sequencing analysis were then performed, as described previously Sato et al., 2007) . Amplified bisulfite-sequencing PCR products were cloned into pESAY-T1 vector (Transgen, Beijing, China), and five clones from each sample were sequenced. Primer sequences are shown in Supplementary Table S2 .
Analysis of cell proliferation
Cell proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) assay as described previously and 5-ethynyl-2 0 -deoxyuridine incorporation assay, which was carried out using the CellLight TM 5-ethynyl-2 0 -deoxyuridine imaging detection kit (RiboBio) according to the manufacturer's instructions.
Analysis of colony formation
For clonogenicity analysis, 48 h after transfection, 1000 viable transfected cells were placed in six-well plates and maintained in complete medium for 2 weeks. Colonies were fixed with methanol and stained with methylene blue.
Analysis of tumorigenicity in nude mice
All experimental procedures involving animals were in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publications nos. 80-23, revised 1996) and were performed according to the institutional ethical guidelines for animal experiment.
The tumorigenicity of HepG2 cells was measured as reported previously (Fabbri et al., 2007; Mercatelli et al., 2008) . HepG2 cells were transfected in vitro with 100 nM (final concentration) NC or miR-520e by using Lipofectamine RNAiMAX (Invitrogen). At 48 h after transfection, 1.5 Â 10 6 viable cells were injected subcutaneously into the right flanks of 4-to 6-week-old female BALB/c athymic nude mice, five mice per group. Tumor growth was measured after 6 days from injection and then every 3 days. At 30 days after injection, mice were killed and tumors were weighed after necropsy. Tumor volume (V) was monitored by measuring the length (L) and width (W) with calipers and calculated with the formula (L Â W 2 ) Â 0.5. A total of 1 Â 10 6 viable HepG2 cells were injected subcutaneously into both flanks of 4-to 6-week-old female BALB/c athymic nude mice. The tumor size was measured daily until the tumor reached 50 mm 3 . Then, 5 mg of synthetic miR520e or NC diluted in Lipofectamine (Invitrogen) solution (100 ml total volume) were intratumorally injected at day 9, 12 and 15 for a total of three injections per tumor. Tumors were measured on the day of the injections and every 3 days after the last injection. After 30 days, the mice were killed, necropsies were performed and tumors were weighed. Tumor volume (V) was monitored by measuring the length (L) and width (W) with calipers and calculated with the formula (L Â W 2 ) Â 0.5.
Luciferase reporter gene assay Luciferase reporter assay was performed using the DualLuciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Cells of 90% confluence were seeded in 24-well plates. For NIK 3 0 UTR luciferase reporter assay, they were co-transfected with 100 nM NC or miR-520e (200 nM anti-miR-NC or anti-miR-520e), 0.3 mg/well of pGL3-NIK-3 0 UTR-wt or pGL3-NIK-3 0 UTR-mu and 0.1 mg/well of Renilla luciferase plasmids using Lipofectamine 2000 (Invitrogen). For NF-kB luciferase reporter assay, they were co-transfected with 100 nM NC or miR-520e (200 nM anti-miR-NC or antimiR-520e), 0.3 mg/well of pGL3-NF-kB plasmids and 0.1 mg/ well of Renilla luciferase plasmids. Cells were lysed and miR-520e inhibits growth of hepatoma cells S Zhang et al assayed for luciferase activity 48 h after transfection. 100 ml of protein extracts were analyzed in a luminometer.
Statistical analysis
Each experiment was repeated at least three times. Numerical data are presented as mean ± s.d. Unless indicated, the differences between two groups were analyzed using a Student's t-test (two-tailed). Differences were considered statistically significant at Po 0.05. All statistical analysis was performed using SPSS13.0 software (SPSS, Chicago, IL, USA).
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